$BRNS
Barinthus Biotherapeutics PLC

2023 Q4 Form 10-Q Financial Statement

#000141057823002303 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $6.165M
YoY Change -100.0% -100.0% 32347.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.62M $961.0K -$11.13M
YoY Change -32.96% -108.63% -486.8%
% of Gross Profit
Research & Development $6.373M $15.14M $9.744M
YoY Change -47.7% 55.42% 122.92%
% of Gross Profit
Depreciation & Amortization $1.435M $700.0K $1.188M
YoY Change 21.92% -41.08% 1297.65%
% of Gross Profit
Operating Expenses $19.99M $16.11M -$1.388M
YoY Change -38.49% -1260.3% -124.99%
Operating Profit -$16.11M $7.553M
YoY Change -313.23% -236.43%
Interest Expense $564.0K $189.0K $718.0K
YoY Change -74.91% -73.68%
% of Operating Profit 9.51%
Other Income/Expense, Net $1.314M $1.392M -$6.000K
YoY Change 116.83% -23300.0% -100.63%
Pretax Income -$18.11M -$14.71M $7.547M
YoY Change -21.88% -294.95% -264.89%
Income Tax -$820.0K -$603.0K -$674.0K
% Of Pretax Income -8.93%
Net Earnings -$17.29M -$14.07M $8.242M
YoY Change -18.39% -270.74% -280.86%
Net Earnings / Revenue 133.69%
Basic Earnings Per Share -$0.37 $0.22
Diluted Earnings Per Share -$0.45 -$0.37 $0.22
COMMON SHARES
Basic Shares Outstanding 38.57M 38.52M 37.25M
Diluted Shares Outstanding 38.53M 38.16M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.1M $160.3M $200.1M
YoY Change -26.9% -19.89% -14.44%
Cash & Equivalents $142.1M $160.3M $200.1M
Short-Term Investments
Other Short-Term Assets $1.474M $355.0K $130.0K
YoY Change 161.81% 173.08% -73.03%
Inventory
Prepaid Expenses $5.402M $4.510M $7.902M
Receivables $0.00 $0.00 $26.00K
Other Receivables $7.939M $5.891M $4.154M
Total Short-Term Assets $156.9M $171.1M $218.6M
YoY Change -26.35% -21.75% -11.12%
LONG-TERM ASSETS
Property, Plant & Equipment $11.82M $12.27M $6.766M
YoY Change 48.56% 81.33% 554.99%
Goodwill $12.21M $12.21M $12.63M
YoY Change 0.0% -3.33%
Intangibles $25.11M $25.90M $29.06M
YoY Change -11.18% -10.88%
Long-Term Investments
YoY Change
Other Assets $882.0K $1.055M $847.0K
YoY Change -9.63% 24.56% 8.73%
Total Long-Term Assets $57.60M $58.91M $56.86M
YoY Change 0.76% 3.6% 436.82%
TOTAL ASSETS
Total Short-Term Assets $156.9M $171.1M $218.6M
Total Long-Term Assets $57.60M $58.91M $56.86M
Total Assets $214.5M $230.0M $275.5M
YoY Change -20.61% -16.52% 7.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.601M $5.145M $2.411M
YoY Change -57.28% 113.4% 80.33%
Accrued Expenses $11.00M $13.42M $11.51M
YoY Change 29.47% 16.64% 137.84%
Deferred Revenue $111.0K
YoY Change -43.37%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $12.60M $18.57M $14.03M
YoY Change 2.91% 32.34% 120.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.325M $1.278M $711.0K
YoY Change 37.31% 79.75% -90.8%
Total Long-Term Liabilities $1.325M $1.278M $711.0K
YoY Change 37.31% 79.75% -90.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.60M $18.57M $14.03M
Total Long-Term Liabilities $1.325M $1.278M $711.0K
Total Liabilities $27.51M $34.37M $31.33M
YoY Change 1.88% 9.7% 122.19%
SHAREHOLDERS EQUITY
Retained Earnings -$176.6M -$159.3M -$82.05M
YoY Change 71.12% 94.14% -12.22%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $186.8M $195.4M $243.8M
YoY Change
Total Liabilities & Shareholders Equity $214.5M $230.0M $275.5M
YoY Change -20.61% -16.52% 7.37%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$17.29M -$14.07M $8.242M
YoY Change -18.39% -270.74% -280.86%
Depreciation, Depletion And Amortization $1.435M $700.0K $1.188M
YoY Change 21.92% -41.08% 1297.65%
Cash From Operating Activities -$19.60M -$11.19M $11.88M
YoY Change 72.82% -194.17% -688.9%
INVESTING ACTIVITIES
Capital Expenditures -$153.0K $36.00K -$2.406M
YoY Change -126.11% -101.5% 1779.69%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $388.0K
YoY Change -100.0%
Cash From Investing Activities $153.0K -$36.00K -$2.018M
YoY Change -126.11% -98.22% 1476.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 109.0K 46.00K 0.000
YoY Change -77.48% -100.0%
NET CHANGE
Cash From Operating Activities -19.60M -11.19M 11.88M
Cash From Investing Activities 153.0K -36.00K -2.018M
Cash From Financing Activities 109.0K 46.00K 0.000
Net Change In Cash -19.34M -11.18M 9.866M
YoY Change 68.99% -213.33% -379.25%
FREE CASH FLOW
Cash From Operating Activities -$19.60M -$11.19M $11.88M
Capital Expenditures -$153.0K $36.00K -$2.406M
Free Cash Flow -$19.45M -$11.23M $14.29M
YoY Change 63.05% -178.57% -856.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001828185
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38546594
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38546594
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
37683531
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37683531
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40367
dei Entity Registrant Name
EntityRegistrantName
BARINTHUS BIOTHERAPEUTICS PLC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
Unit 6-10, Zeus Building Rutherford Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Harwell
dei Entity Address City Or Town
EntityAddressCityOrTown
Didcot
dei Entity Address Country
EntityAddressCountry
GB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
OX11 0DF
dei City Area Code
CityAreaCode
+44 (0)
dei Local Phone Number
LocalPhoneNumber
1865 818 808
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38565272
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
160309000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
194385000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
323000
CY2022Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
5524000
CY2023Q3 vacc Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
4172000
CY2022Q4 vacc Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
4541000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6584000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2255000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8268000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
171065000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
213041000
CY2023Q3 us-gaap Goodwill
Goodwill
12209000
CY2022Q4 us-gaap Goodwill
Goodwill
12209000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12269000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7957000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25898000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28269000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7474000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7753000
CY2023Q3 us-gaap Other Assets
OtherAssets
1055000
CY2022Q4 us-gaap Other Assets
OtherAssets
976000
CY2023Q3 us-gaap Assets
Assets
229970000
CY2022Q4 us-gaap Assets
Assets
270205000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5145000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3748000
CY2023Q3 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
11923000
CY2022Q4 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8061000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1501000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
433000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18569000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12242000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11202000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8340000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1797000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1711000
CY2023Q3 vacc Deferred Tax Liability Net
DeferredTaxLiabilityNet
1521000
CY2022Q4 vacc Deferred Tax Liability Net
DeferredTaxLiabilityNet
3746000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1278000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
965000
CY2023Q3 us-gaap Liabilities
Liabilities
34367000
CY2022Q4 us-gaap Liabilities
Liabilities
27004000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000025
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000025
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
38546594
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37683531
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
385707000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
379504000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159297000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103243000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-31099000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-33460000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
195398000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
242896000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
205000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
305000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
195603000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
243201000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
229970000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
270205000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6165000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
802000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38246000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15144000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9744000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38501000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30165000
CY2023Q3 vacc General And Administrative Income Expense
GeneralAndAdministrativeIncomeExpense
961000
CY2022Q3 vacc General And Administrative Income Expense
GeneralAndAdministrativeIncomeExpense
-10815000
vacc General And Administrative Income Expense
GeneralAndAdministrativeIncomeExpense
26227000
vacc General And Administrative Income Expense
GeneralAndAdministrativeIncomeExpense
-12971000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
16105000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
-1071000
us-gaap Operating Expenses
OperatingExpenses
64728000
us-gaap Operating Expenses
OperatingExpenses
17194000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16105000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
7236000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63926000
us-gaap Operating Income Loss
OperatingIncomeLoss
21052000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
196000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1024000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2306000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1776000
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-7000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
11000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-21000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000
CY2023Q3 vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
1205000
CY2022Q3 vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
-724000
vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
2921000
vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
1150000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
308000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1392000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
311000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5514000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2980000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14713000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7547000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58412000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
24032000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-603000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-674000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2452000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-14110000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
8221000
us-gaap Profit Loss
ProfitLoss
-56157000
us-gaap Profit Loss
ProfitLoss
26484000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-21000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-103000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-47000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14072000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
8242000
us-gaap Net Income Loss
NetIncomeLoss
-56054000
us-gaap Net Income Loss
NetIncomeLoss
26531000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38533833
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37247123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38320208
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37213787
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38533833
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38156564
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38320208
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38226092
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.71
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.69
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-14110000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
8221000
us-gaap Profit Loss
ProfitLoss
-56157000
us-gaap Profit Loss
ProfitLoss
26484000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7820000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19940000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2364000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-42730000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-21930000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-11719000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-53793000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16246000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-48000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-51000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-100000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-122000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21882000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11668000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53693000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16124000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
243201000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2222000
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1789000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4580000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-18223000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
233569000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1990000
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
123000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5604000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-23824000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
217462000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57000
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
14000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7820000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-14110000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
195603000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
252562000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3984000
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5983000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2574000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
253137000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2748000
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16807000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
15689000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
254767000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1104000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19940000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
8221000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
244152000
us-gaap Profit Loss
ProfitLoss
-56157000
us-gaap Profit Loss
ProfitLoss
26484000
us-gaap Share Based Compensation
ShareBasedCompensation
4269000
us-gaap Share Based Compensation
ShareBasedCompensation
7836000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3994000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3146000
vacc Non Cash Lease Expenses
NonCashLeaseExpenses
787000
vacc Non Cash Lease Expenses
NonCashLeaseExpenses
786000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-879000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
36578000
us-gaap Interest Expense
InterestExpense
21000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
86000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
943000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
348000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2254000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2403000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5800000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6162000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5249000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2949000
vacc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-426000
vacc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-1163000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
417000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
142000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5234000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5066000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-43000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
73000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
171000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31322000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3088000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5566000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5552000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
388000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5566000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5164000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1926000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
163000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
159000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1763000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-159000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1049000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5539000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34076000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13950000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194385000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214054000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160309000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200104000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
219000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2400000
vacc Asset Retirement Obligations
AssetRetirementObligations
287000
vacc Asset Retirement Obligations
AssetRetirementObligations
826000
CY2023Q3 vacc Changes To Right Of Use Asset Resulting From Lease Reassessment Event
ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent
88000
CY2022Q3 vacc Changes To Right Of Use Asset Resulting From Lease Reassessment Event
ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent
3000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
160300000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159300000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-14110000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
8221000
us-gaap Profit Loss
ProfitLoss
-56157000
us-gaap Profit Loss
ProfitLoss
26484000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue,income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</p>
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6600000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1100000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18700000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
39100000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-21000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-103000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-47000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14072000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
8242000
us-gaap Net Income Loss
NetIncomeLoss
-56054000
us-gaap Net Income Loss
NetIncomeLoss
26531000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38533833
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37247123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38320208
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37213787
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
909441
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1012304
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38533833
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38156564
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38320208
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38226092
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.71
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.69
CY2023Q3 us-gaap Depreciation
Depreciation
700000
us-gaap Depreciation
Depreciation
1600000
CY2022Q3 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
800000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000
CY2023 vacc Estimated Amortization Expense Of Intangible Assets
EstimatedAmortizationExpenseOfIntangibleAssets
3200000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4510000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5887000
CY2023Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1719000
CY2022Q4 vacc Lease Incentive Receivables Current
LeaseIncentiveReceivablesCurrent
1770000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
355000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
611000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6584000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8268000
CY2023Q3 vacc Accrued Manufacturing And Clinical Expenses Current
AccruedManufacturingAndClinicalExpensesCurrent
6791000
CY2022Q4 vacc Accrued Manufacturing And Clinical Expenses Current
AccruedManufacturingAndClinicalExpensesCurrent
2997000
CY2023Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
37000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
9000
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1720000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1925000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
979000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
928000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1081000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1270000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1315000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
932000
CY2023Q3 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
11923000
CY2022Q4 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8061000
CY2023Q3 vacc Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2023Q3 vacc Percentage Of Shares Necessary To Exercise Preemptive Rights
PercentageOfSharesNecessaryToExercisePreemptiveRights
0.75
vacc Period Of Preemptive Rights To Be Exercised
PeriodOfPreemptiveRightsToBeExercised
P5Y
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
57000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1104000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4269000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7836000
CY2021Q3 vacc Number Of Square Feet Under Lease Agreement
NumberOfSquareFeetUnderLeaseAgreement
31000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7474000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7753000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1501000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
433000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11202000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8340000
us-gaap Operating Lease Payments
OperatingLeasePayments
396000
us-gaap Operating Lease Payments
OperatingLeasePayments
1569000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
152000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
189000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
356000
CY2023Q3 vacc Fixed Lease Costs
FixedLeaseCosts
192000
CY2022Q3 vacc Fixed Lease Costs
FixedLeaseCosts
258000
vacc Fixed Lease Costs
FixedLeaseCosts
787000
vacc Fixed Lease Costs
FixedLeaseCosts
786000
CY2023Q3 us-gaap Lease Cost
LeaseCost
192000
CY2022Q3 us-gaap Lease Cost
LeaseCost
410000
us-gaap Lease Cost
LeaseCost
976000
us-gaap Lease Cost
LeaseCost
1142000
CY2023Q3 vacc Lessee Operating Lease Receivable Remainder Of Fiscal Year
LesseeOperatingLeaseReceivableRemainderOfFiscalYear
-233000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1737000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1889000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1913000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1937000
CY2023Q3 vacc Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
9835000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17544000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4841000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12703000

Files In Submission

Name View Source Status
0001410578-23-002303-index-headers.html Edgar Link pending
0001410578-23-002303-index.html Edgar Link pending
0001410578-23-002303.txt Edgar Link pending
0001410578-23-002303-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230930.xsd Edgar Link pending
tmb-20230930x10q.htm Edgar Link pending
tmb-20230930x10q001.jpg Edgar Link pending
tmb-20230930xex10d1.htm Edgar Link pending
tmb-20230930xex31d1.htm Edgar Link pending
tmb-20230930xex31d2.htm Edgar Link pending
tmb-20230930xex32d1.htm Edgar Link pending
tmb-20230930_def.xml Edgar Link unprocessable
tmb-20230930_lab.xml Edgar Link unprocessable
tmb-20230930_pre.xml Edgar Link unprocessable
tmb-20230930x10q_htm.xml Edgar Link completed
tmb-20230930_cal.xml Edgar Link unprocessable